๐ฐ Between Oct News
Between Oct News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Between Oct. Real-time updates on events, politics, business and more.
April 6, 2024
The Israeli army continued Friday, the bombing and shelling of various parts of the Gaza Strip, killing and wounding dozens of Palestinians, including many ...
April 5, 2024
1. Therapeutic response at days 10-13 was greater in the gepotidacin group compared to the nitrofurantoin group across both trials. 2. Gepotidacin use was associated with diarrhea as the most common adverse event and no significant fatalities were reported. Evidence Rating Level: 1 (Excellent) Study Rundown: Urinary tract infections (UTIs) affect a large portion of
April 4, 2024
1. Patients in the thrombectomy plus medical care group reported a significantly lower mRS score at the 1-year follow-up compared to those in the medical care alone group. 2. 1-year mortality in the thrombectomy group was lower than in the medical care alone group. Evidence Rating Level: 1 (Excellent) Study Rundown: Endovascular thrombectomy is known
February 3, 2024
1. 92.4% of children in high-income countries had heterozygous familial hypercholesterolemia compared to 48.0% in non-high-income countries. 2. The majority of patients with confirmed heterozygous familial hypercholesterolemia were not on any lipid-lowering medication. Evidence Rating Level: 2 (Good) Study Rundown: Familial hypercholesterolemia affects more than 450,000 children worldwide each year, yet only a small proportion
February 1, 2024
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. 2. Grade 3 or worse adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A previous large-scale trial has shown improved overall survival among patients with cervical cancer treated with
January 10, 2024
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. 1% of patients in each group experienced treatment-related mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer. This randomized controlled trial
December 15, 2023
1. Low-dose amitriptyline was associated with a marked decrease in IBS-SSS score at 6 months compared to placebo. 2. There were 5 serious adverse reactions (2 in the amitriptyline group and 3 in the placebo group). Evidence Rating Level: 1 (Excellent) Study Rundown: Irritable bowel syndrome (IBS) is a functional disorder that is managed through dietary changes
December 9, 2023
1. Low-dose amitriptyline was associated with a marked decrease in IBS-SSS score at 6 months compared to placebo. 2. There were 5 serious adverse reactions (2 in the amitriptyline group and 3 in the placebo group). Evidence Rating Level: 1 (Excellent) Study Rundown: Irritable bowel syndrome (IBS) is a functional disorder that is managed through
November 17, 2023
GEORGE TOWN (Nov 17): Allegations of the unity governmentโs involvement in the defection of Parti Pribumi Bersatu Malaysia (Bersatu) lawmakers could ultimately undermine the ruling coalition if proven to be true, according to political experts. Universiti Sains Malaysia political analyst Prof Ahm
October 18, 2023
Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.